Partner
Engagement
Our Hub brings together leading UK expertise in materials science, regenerative medicine, advanced manufacturing to address one of the most pressing challenges in the field: the sustainable, affordable manufacture of mesenchymal stromal/stem cells (MSCs).
These regenerative cells have the potential to revolutionise therapies across a range of diseases — but realising that potential requires a step-change in how they are produced.
We unite an interdisciplinary team with strengths in non-invasive measurement, additive manufacturing, and materials-driven understanding of MSC growth. This collaborative approach is essential.
Engagement with NHS, patients/public and relevant charity is central to our approach.
Driving Innovation with Industry
The Hub structure enables us to engage industry partners flexibly and meaningfully, to ensure routes to scalable production. Working closely with our industry partners to co-develop solutions that meet the practical challenges of scaling MSC-based therapies.
This is more than academic research — it’s a mission to transform clinical and manufacturing practice.
We’ve embedded flexible funding within the Hub to:
-
Launch exploratory joint projects with industry and academia
-
Enable rapid engagement with emerging technologies
-
Support PDRA and industrial mobility, enhancing training and cross-sector knowledge exchange
-
Bring new partners into the Hub through agile project development
Through these efforts, our Hub provides a dynamic platform for industry-academic collaboration, capable of responding to emerging challenges and delivering high-impact solutions in regenerative medicine and beyond.
Getting ready with the NHS and patients
As we launch new technologies, we need to responsibly engage public and patients, through appropriate charity connections. This will allow us to understand need, drive the push for new approaches and help us to train our researchers.
We will achieve this through a number of mechanisms, notably our Research Together events.
We also link to clinicians, Pharma and policy makers in the NHS to help get ready for uptake of the cell therapies our approaches will enable.
Our Partners
In addition to the academic partners working on the project, we have a variety of leading names from industry, clinical practice and the charity & public sectors.
Mainstream is a collaboration between three world-class academic institutions and the UK National Health Service.
